Human ProcartaPlex 13-Plex Human Cell ProcartaPlex targets 13 proliferation and metastasis proteins using Luminex xMAP technology. Simultaneous detection of these targets helps researchers study processes...
Human ProcartaPlex 13-Plex Human Cell ProcartaPlex targets 13 proliferation and metastasis proteins using Luminex xMAP technology. Simultaneous detection of these targets helps researchers study processes such as tumourgenesis, invasion and metastasis. Analysis of these soluble biomarkers could help inform the biology of cancer pathways.
ProcartaPlex preconfigured panels are widely tested for combinability, interference and cross-reactivity of analyses to provide the highest level of validation and accuracy. All ProcartaPlex panels are supplied with the reagents necessary to perform the dosage.
Target list [microbead region]: AFP (alpha-fetoprotein) [15], ADAM12 [33], beta-catenine [75], CD171 (NCAM-L1) [66], CD66f (PSBG-1) [51], galectin-1 [46], hCG [56], HO-1 (heme oxygenase 1) [30], IGFBP-1 [20], N-cadherine [14], nectine-4 [45], PAPP-A [39], thrombomodulin (TM) 1 [73]
ProcartaPlex immunoassays are based on the principle of a sandwich-type ELISA, using two highly specific antibodies binding to different epitopes of a protein to simultaneously quantify all protein targets using a Luminex instrument. ProcartaPlex multiplex assays require only 25 µl plasma or serum, or 50 µl cell culture supernatant, and only four hours to obtain analyzed results.
The characteristics include:
• Reproducible and reliable results — validated in panel to the highest industry standard, with tests for protein target combinationability and cross-reactivity
•More results per sampler — allows multiple protein targets to be achieved simultaneously in a single sample of 25 – 50 µl
•High-reference multiplexing platform with well established Luminex technology for protein detection and quantification
ProcartaPlex assays use Luminex xMAP (multianalyte profiling) technology for simultaneous detection and quantification of up to 80 protein targets in a single 25 –50 µl sample of plasma, serum, cell culture supernatant and other body fluids.
Luminex balls in the ProcartaPlex assay are coloured internally with precise proportions of red and infrared fluorophores to create specific signatures that can be identified by Luminex xMAP detection systems (e.g. Luminex 200, Flexmap 3D and MAGPIX). Like the ELISA sandwich assay, ProcartaPlex uses paired antibody pairs to identify the protein of interest. In multiplexed assays, each single spectral microbead is marked with antibodies specific to a single target protein and the bound proteins are identified with biotinyl antibodies and streptavidine–R-phycoerythrin (RPE). The combination of protein-specific antibodies with a separate microbead allows for the analysis of several targets in a single well.
The most significant difference between ProcartaPlex and ELISA is that the capture antibody in the ProcartaPlex assay is combined with a microbead and is not absorbed into the microplate well, so that the ProcartaPlex assay reagents are floating in the solution. For detection purposes, Luminex 200, for example, contains two lasers: one to distinguish the spectral signature from each microbead and one to quantify the amount of fluorescence of RPE. The latter is proportional to the amount of protein present in the sample. Multiplex ProcartaPlex assays can profile more target proteins using a significantly smaller sample at the same time as it is necessary to make a traditional ELISA sandwich.
ProcartaPlex multiplex panels are available in several formats for six species (human, mouse, rat, non-human primate, porcine and canine).